Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Response Genetics's share price for the quarter that ended in Dec. 2015 was $0.0009. Response Genetics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2015 was 13.65 Mil. Therefore, Response Genetics's market cap for the quarter that ended in Dec. 2015 was $0.01 Mil.
Response Genetics's quarterly market cap
increased
from Dec. 2014 ($12.28 Mil) to Mar. 2015 ($17.07 Mil) but then
declined
from Mar. 2015 ($17.07 Mil) to Dec. 2015 ($0.01 Mil).
Response Genetics's annual market cap
declined
from Dec. 2013 ($44.91 Mil) to Dec. 2014 ($12.28 Mil) and
declined
from Dec. 2014 ($12.28 Mil) to Dec. 2015 ($0.01 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Response Genetics's Enterprise Value for Today is $0.00 Mil.
Response Genetics (OTCPK:RGDXQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Response Genetics Market Cap Related Terms
Response Genetics Market Cap Historical Data
* Premium members only.
The historical data trend for Response Genetics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Response Genetics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Response Genetics Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Market Cap distribution charts can be found below:
* The bar in red indicates where Response Genetics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Response Genetics's Market Cap for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Response Genetics (RGDXQ) has a Market Cap of $0.00 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Response Genetics and its competitors.
Is Response Genetics' Market Cap too high?
Response Genetics' current Market Cap is $0.00 Mil.
How does Response Genetics' Market Cap compare to PSID and GBSN?
Response Genetics' Market Cap of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. The industry median Market Cap is 58.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 58.14, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Response Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 58.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Response Genetics's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Market Cap is $0.00 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGDXQ has been successfully added to your 